

Guardian Research Network

Translating data into cures.

Unlock the GRN difference—deep real world data with sophisticated analytics to drive development

With an avalanche of healthcare data generated, it's easy to be overwhelmed by the influx of valuable information. Curating doctors' notes, genetic profiles, bio-specimens, treatment progressions and more, can be perplexing.


Delivering relevant treatments based on real world therapeutic data—that's the challenge. Yet, taking advantage of mountains of healthcare data requires confidence. And assurance that comes with technologically sophisticated analysis based on medical acumen.

Real world data science is an evolving discipline, but **Guardian Research Network** (GRN) has the experience to help you drive development and speed regulatory approvals.

You get to bring safe and effective new therapies or diagnostics to market quickly. We get a little closer to our non-profit mission of accelerating cures for life threatening diseases like cancer.

Prowess and perspective

At GRN, we get novel ideas across the finish line. Using our network's protected PHI and Part 11-compliant database, we harmonize data for FDA-auditable analysis that produces evidence for regulatory submission. GRN's detailed clinical



Sample real-time dashboard calculation of colorectal cancer patients available for clinical research trials.

insight, combined with your specifics, improves study design, reduces amendments, enhances recruitment and reduces cost.

We create a more complete picture of patient experiences and give you greater insight into drug development. That means discerning assessments and possibilities. Not failed protocols, limited records or confounding patients. But the ability to:

- **Action real world data** and sophisticated models to unlock clinically-valuable intelligence
- **Translate structured and unstructured data into value** by harnessing AI, ML and NLP
- **Access the right number and type of patients** to submit your filing
- **Garner flexibility and added answers**, closing the loop back to patients and physicians
- **Collaborate with EMR and medical specialists** who understand healthcare and regulations

GRN Quick Facts

2m+ ONCOLOGY PATIENTS
21 CANCER SUBTYPES
130 ANALYTICS STUDIES
308m+ MEDICATION RECORDS REVIEWED
360m CLINICAL NOTES DECIPHERED
38.5m+ SPECIALTY, PATHOLOGY & RADIOLOGY REPORTS STUDIED
78.3m CLINICAL PROCEDURES ANALYZED
 ONCOLOGY-DRIVEN SINCE **2014**

Deep, rich oncology data

Life sciences customers tell us regularly “your data is so much more detailed than others.” Based on our research-grade, regulatory-compliant clinical data, GRN is the only one that can actually say YES, WE CAN do that.

GRN is the only organization who dependably gets the 30, 300 or 3,000 patients you actually need to file a successful FDA dossier. While we may not have the largest patient pool, we do have the highest quality detail as a conduit for complex analyses. Namely, meaningful data interpretation, innovative approaches and strategic results.

With more than 2 million cancer patients, our data goes well beyond traditional EMR/EHRs to include:

- tumor morphology, histology and stage
- labs, specialized tests and imaging
- common, advanced & molecular biomarkers
- genetic profiles & genomic sequencing
- first, second, third, etc., course of treatment
- patient characteristics and status, including appointment schedules
- tele-health, pharmacy and insurance

Data science savvy, proprietary technology

With our advanced analysis, we enable data-driven informatics to enhance retrospective and prospective analyses. Using proven models, data visualization and advanced technologies, we help you expedite precision medicine, support biomarker discovery and validation, and/or drive companion diagnostics development.

Backed by board-certified physicians and oncology research specialists, our expertise comes with a marked medical perspective. Our robust analytics and industry perspective have contributed positively to some of the most challenging oncology issues. And, because we’re a consortium of health systems, including community-based hospitals, we have unparalleled access to physicians, nurses and clinicians who understand study outliers, patients lost to follow-up, and the causes and clinical impacts that can minimize risk.

Ultimately, you have the comfort and attention to detail you expect, plus the benefits of faster approvals that come from intelligent clinical design and knowledgeable analysis.

THE GRN ADVANCED ANALYTICS DIFFERENCE

Experience is our strength and your biggest asset. See some of the analytics projects in our data science repertoire:

VIRTUAL COMPARATOR SIMULATION and de-identified aggregate analyses in a study of survival rates of African American women with triple negative breast cancer

RWD OUTCOMES AND POOLED CLINICAL TRIAL COMPARISONS to assess the response, progression and survival in cases of relapsed-refractory multiple myeloma

RETROSPECTIVE DATA AND COHORT STUDY among histologically-segmented soft tissue sarcoma patients over the past 10 years

MOLECULARLY-SELECTED PATIENT INVESTIGATION of PDL1 inhibitors in NSC lung cancer with molecular alterations

PHASE II, III & IV ANALYTICS identifying archival formalin-fixed, paraffin-embedded tissue for molecular characterization of prospective patients in validation cohorts

NON-INVASIVE AI/ML ANALYTICS to extract complex clinical note data into discrete data fields for analysis

10-YEAR PATIENT JOURNEY ANALYSIS with deep sets of multi-domain longitudinal data across cohorts for multiple oncology subsets along with disease histories

CONSIDER A MASTER AGREEMENT TODAY!

GRN offers master agreements for data analytics that can help you get studies started sooner—with no need for additional contractual timing. Contact your GRN representative for more on how a master agreement can bring together data science, proprietary technology and sophisticated analytics to accelerate your research and development.